PHVS icon

Pharvaris

14.83 USD
-0.87
5.54%
At close Apr 1, 4:00 PM EDT
1 day
-5.54%
5 days
-3.45%
1 month
-3.20%
3 months
-20.01%
6 months
-19.53%
Year to date
-20.01%
1 year
-31.47%
5 years
-48.86%
10 years
-48.86%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

58% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 12

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

6% more funds holding

Funds holding: 51 [Q3] → 54 (+3) [Q4]

3% more capital invested

Capital invested by funds: $834M [Q3] → $856M (+$21.6M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

0.74% less ownership

Funds ownership: 83.4% [Q3] → 82.66% (-0.74%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$55
271%
upside
Avg. target
$55
271%
upside
High target
$55
271%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Citizens Capital Markets
Jonathan Wolleben
0 / 0 met price target
271%upside
$55
Market Outperform
Reiterated
3 Mar 2025
JMP Securities
Jonathan Wolleben
0 / 0 met price target
271%upside
$55
Market Outperform
Maintained
31 Jan 2025

Financial journalist opinion

Based on 3 articles about PHVS published over the past 30 days

Neutral
GlobeNewsWire
16 hours ago
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema.
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
Neutral
GlobeNewsWire
4 weeks ago
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), highlighted safety and efficacy data of deucrictibant, which is currently being evaluated in two pivotal Phase 3 studies, following long-term dosing in the prophylactic and on-demand settings at the American Academy of Allergy, Asthma, & Immunology's Annual Scientific Meeting (AAAAI) and World Allergy Organization (WAO) Joint Congress, which was held from February 28–March 3, 2025, in San Diego, CA.
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Neutral
GlobeNewsWire
4 weeks ago
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows:
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
Neutral
GlobeNewsWire
2 months ago
Pharvaris Outlines 2025 Strategic Priorities
ZUG, Switzerland, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema (AAE), today outlined its strategic priorities for 2025.
Pharvaris Outlines 2025 Strategic Priorities
Neutral
GlobeNewsWire
4 months ago
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business updates.
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Neutral
GlobeNewsWire
4 months ago
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference, taking place from November 11-13, 2024, at the InterContinental Boston. Details are as follows:
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Neutral
GlobeNewsWire
5 months ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows:
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
Neutral
GlobeNewsWire
5 months ago
Pharvaris to Host Virtual Investor Event on October 23, 2024
ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced it will host a virtual investor event to discuss the unmet need in both the prophylactic and on-demand treatment of HAE attacks, the potential of deucrictibant to address to needs, and the current HAE market dynamics, on Wednesday, October 23, 2024, at 10:00 a.m. ET/16:00 CET. To register, click here.
Pharvaris to Host Virtual Investor Event on October 23, 2024
Neutral
GlobeNewsWire
5 months ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of six abstracts, two for oral presentation and four for poster presentation, at the 2024 Global Angioedema Forum – HAEi Global Leadership Workshop, taking place in Copenhagen, Denmark, from Oct. 4-5, 2024. Details are as follows:
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
Neutral
GlobeNewsWire
6 months ago
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the planned initiation of CHAPTER-3, the pivotal Phase 3 study of deucrictibant extended-release tablets for the prophylactic treatment of HAE; announced its intention to pursue clinical development of deucrictibant in a newly named indication, acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH); and presented a robust data set highlighting the differentiating characteristics of deucrictibant.
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
Charts implemented using Lightweight Charts™